Cosentyx for Hidradenitis Suppurativa

What does the FDA expansion mean for hidradenitis suppurativa?

Hidradenitis suppurativa (HS) is a long-term inflammatory skin disease that often affects areas where skin rubs together, including the armpits and groin. It can cause recurring painful lumps, abscesses, drainage, and scarring. The condition is not caused by poor hygiene and is not contagious. A US FDA expansion of secukinumab’s use gives clinicians another approved medicine to consider for patients who meet the relevant prescribing criteria.

Secukinumab is a monoclonal antibody that blocks interleukin-17A, a signaling protein involved in inflammation. The FDA action concerns a specific medicine and indication; it does not mean the drug is appropriate for every person with HS or that it cures the condition. Treatment decisions depend on disease severity, prior care, medical history, and the risks described in the prescribing information.

How is secukinumab used, and what should patients discuss?

For people considering this treatment, a dermatologist or other qualified clinician can explain the approved regimen, how it is given, and what improvement to expect. HS care may also include wound care, pain management, lifestyle support when relevant, antibiotics for selected situations, or procedures. Because the disease can affect comfort and quality of life, care plans often need to address both active lesions and longer-term effects such as scarring.

Medicines that affect immune pathways can have important safety considerations. Before starting secukinumab, patients should review their infection history, current symptoms, other medicines, and vaccination status with their clinician. They should seek medical advice about signs of infection or other concerning symptoms during treatment and should not stop or change prescribed therapy without discussing it with the prescriber.